2023 World Conference on Lung Cancer (Posters)-P1.24. Mortality Benefit of a 4-Protein Blood-Based Biomarker Panel for Lung Cancer

P1.24. Mortality Benefit of a 4-Protein Blood-Based Biomarker Panel for Lung Cancer - PDF(Abstract)

Pdf Summary

This study investigated the effectiveness of a 4-protein blood-based biomarker panel combined with a clinical risk model in predicting the risk of lethal lung cancer. Data from 552 lung cancer cases and 2,193 non-cases were analyzed from the Prostate Lung Colorectal and Ovarian (PLCO) cohort. Of the lung cancer cases, 70% died from the disease. The 4-protein biomarker panel in combination with the clinical risk model showed improved lung cancer risk estimation compared to either metric alone. The cumulative incidence and hazard ratios for lung cancer death were calculated based on the risk scores. The model showed a high accuracy for predicting lung cancer death, with an area under the curve estimate of 0.88. Individuals with risk scores above the 1.0% 6-year risk threshold had a significantly higher cumulative incidence of lung cancer death compared to those below the threshold. The hazard ratios for test-positive cases were also higher indicating an increased risk. Overall, the study concludes that the blood-based biomarker panel along with the clinical risk model can identify individuals at high risk of lethal lung cancer. This finding could improve the selection process for lung cancer screening, allowing for better targeting of those who would benefit the most.

Asset Subtitle

Edwin Ostrin

Meta Tag

Speaker Edwin Ostrin

Topic Pathology & Biomarkers: Prognostic Biomarkers

Keywords

4-protein biomarker panel

clinical risk model

lethal lung cancer

Prostate Lung Colorectal and Ovarian

PLCO cohort

lung cancer cases

non-cases

cumulative incidence

hazard ratios

area under the curve estimate